NEW YORK--(BUSINESS WIRE)--The Rosen Law Firm, a global investor rights firm, reminds purchasers of Xoma Corporation (NASDAQ:XOMA) securities during the period from November 6, 2014 through July 21, 2015 of the important September 22, 2015 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Xoma Corporation investors under the federal securities laws.
To join the Xoma Corporation class action, go to the firm’s website at http://www.rosenlegal.com/cases-684.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email firstname.lastname@example.org or email@example.com for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants made false and/or misleading statements that Xoma Corporation’s EYEGUARD-B clinical trial would succeed and/or exceed projections across the study’s primary endpoint. On July 22, 2015, defendants announced that the Phase 3 EYEGUARD-B study had failed. Consequently, the price of Xoma stock fell by $3.48 per share, or more than 79%, on extremely heavy trading volume.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 22, 2015. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website http://www.rosenlegal.com/cases-684.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at firstname.lastname@example.org or email@example.com.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.